Scientific Advisory Board

Bret Berner, PhD

Brett is currently a formulation consultant and has over 35 years industrial experience in transdermal and oral drug delivery resulting in over a dozen products. Dr. Berner is former CSO of Depomed, VP of Development at Cygnus and Director of Pharmaceutics Research at Ciba-Geigy (now Novartis).

After receiving his PhD in Neurosciences/Physical Chemistry from UCLA, he joined Procter & Gamble as a staff scientist working on novel product research on skin. He is also inventor for over 50 pharmaceutical US patents, editor of 2 books, and author of over 80 journal publications on drug delivery.

Keith Bley, PhD

Keith is currently the Senior Vice President of Development at Antiva Biosciences, which is developing topical treatments for diseases caused by the Human Papilloma Virus.

Before Antiva, he was Senior Vice President of Product Development at NovaBay Pharmaceuticals. At NovaBay, he led drug product development in dermatologic, urologic, and rare disease indications. From 2000 to 2011, Keith was Senior Vice President of Nonclinical R&D at NeurogesX, whose internally developed and approved product, Qutenza® Therapeutics. Keith also held positions in R&D management at Roche Palo Alto and Syntex.

Keith holds a PhD from the Department of Cellular and Molecular Physiology at Yale University, a MA in Philosophy from Columbia University, and a BA in Philosophy from The Catholic University of America.

R Michael Gendreau, MD, PhD

Gendreau has more than 25 years of experience serving as the Chief Medical Officer for both private and public biotechnology companies involved in diagnostics, pharmaceuticals, and medical devices.

His areas of expertise are rheumatology, functional somatic syndromes, chronic and acute pain, schizophrenia, depression, anxiety, and cognition disorders.

Dr. Gendreau was a founding member and Chief Medical Officer of Cypress Bioscience, Inc. He received a BS in Chemistry from Ohio University and MD and PhD degrees in Pharmacology from The Ohio State University.

Stephen Hwang, PhD

Stephen is a clinical pharmacology consultant. He has worked at Johnson & Johnson/Alza, Inhale Therapeutics, ALZA Corporation, and Merck & Co. He has participated in the filing of Testoderm, Nicoderm and Duragesics. Dr. Hwang holds a PhD in Pharmaceutical Chemistry and a master degree (Chemistry) from University of Michigan, Ann Arbor. He obtained his BS degree from Tsing Hua University (Taiwan).

Kenneth D. Krantz, MD, PhD

Kenneth is a consultant and professional manager of medical/scientific enterprises in the areas of pharmaceutical development, clinical regulatory strategy and planning, clinical research and development, product license & acquisition evaluation, strategic planning, and research personnel assessment and training.

Over the past 40 years, he has held senior clinical research positions at major pharma companies (G.D. Searle, Schering-­Plough, Ayerst AHP, Johnson & Johnson), as well as VP, Clinical & Regulatory Affairs at biotech and smaller pharma companies. He received his BS, MD and PhD degrees from the University of Chicago.